- Market Capitalization, $K 347,677
- Shares Outstanding, K 105,999
- Annual Sales, $ 4,920 K
- Annual Income, $ -16,820 K
- 60-Month Beta 1.95
- Price/Sales 59.89
- Price/Cash Flow N/A
- Price/Book 4.72
|Period||Period Low||Period High||Performance|
| || |
-0.20 (-5.73%)since 06/12/20
| || |
+0.79 (+31.60%)since 04/14/20
| || |
+1.21 (+58.17%)since 07/12/19
, /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP)....
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ: MEIP). Such investors are advised to contact at or...
Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis
Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.
Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP
The first step to selecting the right breakout stock is to calculate its support and resistance level.
Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.
Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO.
|Mei Pharma Inc|
|Bioshares Biotech Clinical Trial|
|Alps Medical Breakthroughs ETF|
|Micro-Cap Ishares ETF|
|US Innovative Healthcare Ishares Evolved ETF|
|Russell 2000 Growth Ishares ETF|